Introduction:
These
substances resemble β-lactam molecules, but they have very weak
antibacterial action and therefore we are not classifying them as
antibiotics in nature. They are potent inhibitors of many but not
all bacterial β-lactamases and can protect hydrolyzable penicillins
from inactivation by these enzymes. Beta-lactamase inhibitors are
most active against Ambler class A β-lactamases (plasmid-encoded
transposable element [TEM] β-lactamases in particular), such as
those produced by staphylococci, H. influenzae, N. gonorrhoeae,
salmonella, shigella, E. coli , and K. pneumoniae.
Spectrum
of activity: They
are not good inhibitors of class C β-lactamases, which typically are
chromosomally encoded and inducible, produced by Enterobacter sp,
Citrobacter sp, S. marcescens , and P. aeruginosa , but they do
inhibit chromosomal β-lactamases of B. fragilis and M.
catarrhalis . The three inhibitors differ slightly with respect to
pharmacology, stability, potency, and activity, but these differences
usually are of little therapeutic significance.
Formulations:
Beta-lactamase
inhibitors are available only in fixed combinations with specific
penicillins. The antibacterial spectrum of the combination is
determined by the companion penicillin, not the β-lactamase
inhibitor. An inhibitor extends the spectrum of a penicillin
provided that the inactivity of the penicillin is due to destruction
by β-lactamase and that the inhibitor is active against the
β-lactamase that is produced. Thus, ampicillin-sulbactam is active
against β-lactamase-producing S. aureus and H. influenzae but
not against serratia, which produces a β lactamase that is not
inhibited by sulbactam.
Similarly,
if a strain of P. aeruginosa is resistant to piperacillin, it is
also resistant to piperacillin-tazobactam because tazobactam does not
inhibit the chromosomal β-lactamase produced by P. aeruginosa. The
indications for penicillin-β-lactamase inhibitor combinations are
empirical therapy for infections caused by a wide range of potential
pathogens in both immunocompromised and immunocompetent patients and
treatment of mixed aerobic and anaerobic infections, such as
intra-abdominal infections.
RELATED;
1. PENICILLINS
2. CEPHALOSPORINS
3. PHARMACOLOGY AND THERAPEUTICS
REFERENCES